AriBio completes dosing in global Phase 3 Alzheimer’s trial

AriBio says the last patient has finished dosing in its 1,535-patient global Phase 3 POLARIS-AD study of AR1001 for early Alzheimer’s disease. The company expects topline results later in 2026, a key readout for a once-daily oral drug candidate aimed at a disease with few effective treatment options.

Why it matters: - AriBio is nearing a pivotal readout for AR1001, its lead Alzheimer’s candidate, after completing dosing in a large global Phase 3 study. - The result could shape the next step for a once-daily oral treatment being studied for early Alzheimer’s disease across multiple countries. - The trial’s scale and long duration make the topline data important for investors, clinicians and patients watching the search for disease-modifying options.

What happened: - AriBio said the last patient completed dosing in POLARIS-AD, the company’s global Phase 3 trial of AR1001. - The final patient finished the 52-week treatment period on June 29, 2026. - POLARIS-AD enrolled 1,535 participants at about 230 clinical sites in 13 countries. - The study included sites in the United States, Canada, the United Kingdom, the European Union, South Korea and China. - The first patient was dosed in December 2022 in the United States. - A total of 1,348 participants completed the 52-week treatment period. - AriBio expects to report topline results later in 2026.

The details: - POLARIS-AD is randomized, double-blind and placebo-controlled. - The trial is designed to evaluate the efficacy and safety of AR1001 in patients with early Alzheimer’s disease. - AR1001 is a once-daily oral small molecule and a blood-brain barrier-penetrant phosphodiesterase-5, or PDE5, inhibitor. - The study includes clinical, functional and biomarker assessments intended to support marketing applications in multiple countries. - AriBio said the trial showed a 12.2% discontinuation rate during the 52-week treatment period. - 95.5% of participants who completed the main study chose to enter the optional long-term extension study, representing more than 1,250 participants. - The extension study is expected to continue through July 2027 and is intended to provide longitudinal efficacy and safety data. - AR1001 has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.

Between the lines: - The company is emphasizing execution and tolerability ahead of the primary data readout. - A low dropout rate in a year-long Alzheimer’s trial may signal strong participant engagement and manageable treatment burden, which could matter if efficacy data are positive. - The high uptake of the extension study suggests continued interest in the program, but the drug’s clinical value still depends on the upcoming topline results.

What's next: - Participants will move through the final study safety visit. - AriBio will complete final data collection, data cleaning, database lock and analysis. - The company plans to share topline results later in 2026. - The long-term extension study is expected to run through July 2027. - AriBio’s announcement is available on LinkedIn.

The bottom line: - AriBio has finished dosing in a major Phase 3 Alzheimer’s trial, and the market-moving moment now shifts to the data readout later this year.